'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study

被引：4

作者：

Wilson, Matthew R. R. ^{[1
,4
]}

Haynes, Euan ^{[2
]}

Parsons, Katrina ^{[1
]}

Hopkins, David ^{[1
]}

Robertson, Elizabeth ^{[3
]}

Ferguson, Graeme ^{[1
]}

Quinn, Daire ^{[1
]}

Murray, Jim ^{[3
]}

Osborne, Wendy ^{[2
]}

Leach, Mike ^{[1
]}

McKay, Pam ^{[1
]}

机构：

[1] Beatson West Scotland Canc Ctr, Dept Haematol, Glasgow, Scotland

[2] Newcastle Tyne NHS Fdn Trust, Dept Haematol, Newcastle Upon Tyne, England

[3] Royal United Hosp Bath NHS Trust, Dept Haematol, Bath, England

[4] Beatson West Scotland Canc Ctr, 1053 Great Western Rd, Glasgow G12 0YN, Scotland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 202卷 / 04期

关键词：

chemotherapy; elderly; Hodgkin disease; Hodgkin lymphoma; STUDY-GROUP GHSG; 1ST-LINE THERAPY; ELDERLY-PATIENTS; OPEN-LABEL; BLEOMYCIN; PROCARBAZINE; DACARBAZINE; PHASE-2; DISEASE; TRIAL;

D O I：

10.1111/bjh.18947

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co-morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2-year PFS and OS, 73% (95% CI: 52-94) and 93% (95% CI: 80-100) respectively).

引用

页码：796 / 800

页数：5

共 20 条

[1] A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) [J].

Ballova, V ;

Rüffer, JU ;

Haverkamp, H ;

Pfistner, B ;

Müller-Hermelink, HK ;

Dühmke, E ;

Worst, P ;

Wilhelmy, M ;

Naumann, R ;

Hentrich, M ;

Eich, HT ;

Josting, A ;

Löffler, M ;

Diehl, V ;

Engert, A .

ANNALS OF ONCOLOGY, 2005, 16 (01) :124-131

[2] Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity [J].

Barrett, Aisling ;

Collins, Graham P. .

FRONTIERS IN ONCOLOGY, 2023, 12

[3] Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial [J].

Behringer, Karolin ;

Goergen, Helen ;

Hitz, Felicitas ;

Zijlstra, Josee M. ;

Greil, Richard ;

Markova, Jana ;

Sasse, Stephanie ;

Fuchs, Michael ;

Topp, Max S. ;

Soekler, Martin ;

Mathas, Stephan ;

Meissner, Julia ;

Wilhelm, Martin ;

Koch, Peter ;

Lindemann, Hans-Walter ;

Schalk, Enrico ;

Semrau, Robert ;

Kriz, Jan ;

Vieler, Tom ;

Bentz, Martin ;

Lange, Elisabeth ;

Mahlberg, Rolf ;

Hassler, Andre ;

Vogelhuber, Martin ;

Hahn, Dennis ;

Mezger, Joerg ;

Krause, Stefan W. ;

Skoetz, Nicole ;

Boell, Boris ;

von Tresckow, Bastian ;

Diehl, Volker ;

Hallek, Michael ;

Borchmann, Peter ;

Stein, Harald ;

Eich, Hans ;

Engert, Andreas .

LANCET, 2015, 385 (9976) :1418-1427

[4] The treatment of older Hodgkin lymphoma patients [J].

Boell, Boris ;

Goergen, Helen .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (01) :82-92

[5] Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials [J].

Boell, Boris ;

Goergen, Helen ;

Behringer, Karolin ;

Broeckelmann, Paul J. ;

Hitz, Felicitas ;

Kerkhoff, Andrea ;

Greil, Richard ;

von Tresckow, Bastian ;

Eichenauer, Dennis A. ;

Buerkle, Carolin ;

Borchmann, Sven ;

Fuchs, Michael ;

Diehl, Volker ;

Engert, Andreas ;

Borchmann, Peter .

BLOOD, 2016, 127 (18) :2189-2192

[6] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group [J].

Borchmann, Peter ;

Goergen, Helen ;

Kobe, Carsten ;

Lohri, Andreas ;

Greil, Richard ;

Eichenauer, Dennis A. ;

Zijlstra, Josee M. ;

Markova, Jana ;

Meissner, Julia ;

Feuring-Buske, Michaela ;

Huttmann, Andreas ;

Dierlamm, Judith ;

Soekler, Martin ;

Beck, Hans-Joachim ;

Willenbacher, Wolfgang ;

Ludwig, Wolf-Dieter ;

Pabst, Thomas ;

Topp, Max S. ;

Hitz, Felicitas ;

Bentz, Martin ;

Keller, Ulrich Bernd ;

Kuhnhardt, Dagmar ;

Ostermann, Helmut ;

Schmitz, Norbert ;

Hertenstein, Bernd ;

Aulitzky, Walter ;

Maschmeyer, Georg ;

Vieler, Tom ;

Eich, Hans ;

Baues, Christian ;

Stein, Harald ;

Fuchs, Michael ;

Kuhnert, Georg ;

Diehl, Volker ;

Dietlein, Markus ;

Engert, Andreas .

LANCET, 2017, 390 (10114) :2790-2802

[7] Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial [J].

Cheson, Bruce D. ;

Bartlett, Nancy L. ;

LaPlant, Betsy ;

Lee, Hun J. ;

Advani, Ranjana J. ;

Christian, Beth ;

Diefenbach, Catherine S. ;

Feldman, Tatyana A. ;

Ansell, Stephen M. .

LANCET HAEMATOLOGY, 2020, 7 (11) :E808-E815

[8] Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study [J].

Evens, Andrew M. ;

Connors, Joseph M. ;

Younes, Anas ;

Ansell, Stephen M. ;

Kim, Won Seog ;

Radford, John ;

Feldman, Tatyana ;

Tuscano, Joseph ;

Savage, Kerry J. ;

Oki, Yasuhiro ;

Grigg, Andrew ;

Pocock, Christopher ;

Dlugosz-Danecka, Monika ;

Fenton, Keenan ;

Forero-Torres, Andres ;

Liu, Rachael ;

Jolin, Hina ;

Gautam, Ashish ;

Gallamini, Andrea .

HAEMATOLOGICA, 2022, 107 (05) :1086-1094

[9] Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma [J].

Evens, Andrew M. ;

Advani, Ranjana H. ;

Helenowski, Irene B. ;

Fanale, Michelle ;

Smith, Sonali M. ;

Jovanovic, Borko D. ;

Bociek, Gregory R. ;

Klein, Andreas K. ;

Winter, Jane N. ;

Gordon, Leo I. ;

Hamlin, Paul A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) :3015-+

[10] Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) [J].

Gibb, Adam ;

Pirrie, Sarah J. ;

Linton, Kim ;

Warbey, Victoria ;

Paterson, Kathryn ;

Davies, Andrew J. ;

Collins, Graham P. ;

Menne, Tobias ;

McKay, Pamela ;

Fields, Paul A. ;

Miall, Fiona M. ;

Nagy, Eszter ;

Wheatley, Keith ;

Reed, Rachel ;

Baricevic-Jones, Ivona ;

Barrington, Sally ;

Radford, John .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (01) :63-71

← 1 2 →